Clinical characteristics according to age groups
. | 14 y or younger, n = 54 . | 15 to 18 y, n = 11 . | Older than 18 y, n = 182 . | P* . | |||
---|---|---|---|---|---|---|---|
no. . | % . | no. . | % . | no. . | % . | ||
Age | |||||||
Less than 60 y | 54 | 100 | 11 | 100 | 67 | 37 | |
60 y or older | 0 | 0 | 0 | 0 | 115 | 63 | |
Ann Arbor stage† | |||||||
I or II | 49 | 42 | |||||
III or IV | 69 | 58 | |||||
Sex | |||||||
Female | 16 | 30 | 3 | 27 | 80 | 44 | |
Male | 38 | 70 | 8 | 73 | 100 | 56 | .06 |
Lesions† | |||||||
Extranodal only | 14 | 13 | |||||
Nodal only | 59 | 54 | |||||
Nodal/extranodal | 37 | 34 | |||||
B symptoms | |||||||
No | 26 | 67 | 3 | 43 | 62 | 60 | |
Yes | 13 | 33 | 4 | 57 | 41 | 40 | .56 |
Chemotherapy | |||||||
NHL-BFM backbone like | 50 | 98 | 6 | 75 | 10 | 8 | |
CHOP/COPBLAM like | 0 | 0 | 2 | 25 | 83 | 69 | |
Other | 1 | 2 | 0 | 0 | 27 | 23 | < .001 |
Radiotherapy | |||||||
No | 51 | 100 | 8 | 100 | 80 | 71 | |
Yes | 0 | 0 | 0 | 0 | 32 | 29 | < .001 |
Treatment within NHL-BFM trial | |||||||
Yes | 49 | 91 | 5 | 45 | 0 | 0 | |
No | 5 | 9 | 6 | 55 | 182 | 100 |
. | 14 y or younger, n = 54 . | 15 to 18 y, n = 11 . | Older than 18 y, n = 182 . | P* . | |||
---|---|---|---|---|---|---|---|
no. . | % . | no. . | % . | no. . | % . | ||
Age | |||||||
Less than 60 y | 54 | 100 | 11 | 100 | 67 | 37 | |
60 y or older | 0 | 0 | 0 | 0 | 115 | 63 | |
Ann Arbor stage† | |||||||
I or II | 49 | 42 | |||||
III or IV | 69 | 58 | |||||
Sex | |||||||
Female | 16 | 30 | 3 | 27 | 80 | 44 | |
Male | 38 | 70 | 8 | 73 | 100 | 56 | .06 |
Lesions† | |||||||
Extranodal only | 14 | 13 | |||||
Nodal only | 59 | 54 | |||||
Nodal/extranodal | 37 | 34 | |||||
B symptoms | |||||||
No | 26 | 67 | 3 | 43 | 62 | 60 | |
Yes | 13 | 33 | 4 | 57 | 41 | 40 | .56 |
Chemotherapy | |||||||
NHL-BFM backbone like | 50 | 98 | 6 | 75 | 10 | 8 | |
CHOP/COPBLAM like | 0 | 0 | 2 | 25 | 83 | 69 | |
Other | 1 | 2 | 0 | 0 | 27 | 23 | < .001 |
Radiotherapy | |||||||
No | 51 | 100 | 8 | 100 | 80 | 71 | |
Yes | 0 | 0 | 0 | 0 | 32 | 29 | < .001 |
Treatment within NHL-BFM trial | |||||||
Yes | 49 | 91 | 5 | 45 | 0 | 0 | |
No | 5 | 9 | 6 | 55 | 182 | 100 |
Percentages were calculated on the basis of the number of cases that could be evaluated; data were not available for all cases. Percentages may not total 100 because of rounding.
P values were calculated with the use of Fisher exact test or the chi-square test and refer to differences between the cases 14 years or younger and older than 18 years.
Parameters not assessed in patients 18 years or younger.